However, given that activation of the RAAS is still likely to be a major contributor to hypertension in children with ADPKD, we support the use of ACE inhibitors and angiotensin receptor blockers as the first-line anti-hypertensive agent in this population. Here, ACE is linked to autosomal dominant polycystic kidney disease.